Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease
Endpoints News covers a SPAC-backed biotech that has reached the Nasdaq, alongside AstraZeneca's Phase 3 win in a rare children's bone disease.
AstraZeneca
NASDAQ: AZN, LSE: AZN ~$220B (global mega-cap) MCAP
AstraZeneca is a global biopharmaceutical company developing and commercializing medicines across oncology, cardiovascular, renal, metabolism, and respiratory diseases. The company has a deep and diversified late-stage pipeline including Tagrisso, Imfinzi, Enhertu, Calquence, and Farxiga, with multiple Phase 3 readouts and launches scheduled for 2026 across multiple therapeutic areas.
Company Info
Sector:Pharmaceutical / Diversified Biopharma
Headquarters:Cambridge, United Kingdom
Founded:1999
Website:www.astrazeneca.com/
Upcoming Milestones & Key Dates
Q3 2026
Earnings
H1 2026 earnings and pipeline update
H2 2026
Clinical Trial
Multiple Phase 3 readouts across oncology and rare-disease franchises
H2 2026
Regulatory
FDA advisory committee for SPAC-backed biotech on Nasdaq and pediatric bone-disease program update
Clinical Development Pipeline
Tagrisso (osimertinib) + chemotherapy
Target: Third-generation EGFR TKIEnhertu (trastuzumab deruxtecan)
Target: HER2-directed antibody-drug conjugate (DXd payload)Ultomiris (ravulizumab)
Target: Anti-C5 monoclonal antibody (long-acting)Recent News
Leadership Team
Pascal Soriot
Chief Executive Officer
Aradhana Sarin
Chief Financial Officer
Dr. Susan Galbraith
Executive Vice President, Oncology R&D
Careers & Job Openings